We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

59 hedge funds and large institutions have $32.9M invested in Akoya BioSciences in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

24% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 17

13% more capital invested

Capital invested by funds: $29M → $32.9M (+$3.91M)

0% more funds holding

Funds holding: 5959 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

0.65% less ownership

Funds ownership: 25.08%24.43% (-0.65%)

Holders
59
Holders Change
Holders Change %
0%
% of All Funds
0.85%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
7
Increased
21
Reduced
17
Closed
7
Calls
$104K
Puts
Net Calls
+$104K
Net Calls Change
-$76K

AKYA Hedge Fund Activity: Q3 2024 in Review

59 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q3 2024, worth a combined $32.9M — up 13% from $29M a quarter earlier.

Fund positioning in AKYA was balanced in Q3 2024: 7 funds opened new positions, 7 closed out, 21 added to existing stakes and 17 trimmed.

The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, adding an estimated $1.07M. The largest seller was SVB Wealth, exiting entirely with an estimated $1.21M sold.

  • 59 institutional investors held Akoya BioSciences (AKYA) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $32.9M of Akoya BioSciences stock for Q3 2024, up 13% quarter-over-quarter.
  • 7 funds opened new Akoya BioSciences positions in Q3 2024 and 7 closed out, a net change of 0 holders.
  • The largest Akoya BioSciences buyer in Q3 2024 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $1.07M added.
  • The largest Akoya BioSciences seller in Q3 2024 was SVB Wealth, an estimated $1.21M sold.

Based on aggregated 13F filings for Q3 2024.